Nippon India Pharma Fund - Direct Plan - Growth Plan

Nippon India Pharma Fund - Direct Plan - Growth Plan

Compare
Equity
Direct
Sector - Healthcare
NAV: ₹ 478.69 as on 17-05-2024

About the Fund

Nippon India Pharma Fund - Direct Plan - Growth Plan is an equity fund. This fund was started on 1 January, 2013. The fund is managed by Sailesh Raj Bhan, Kinjal Desai. The fund could potentially beat inflation in the long-run.

Key Parameters

  1. Nippon India Pharma Fund - Direct Plan - Growth Plan has ₹7133 Cr worth of assets under management (AUM) as on Apr 2024 and is more than category average.
  2. The fund has an expense ratio 0.9.
Fund Performance
zero opening, trading, fund transfer fee
6214 people have invested ₹ 2.4Cr in Nippon India Pharma Fund - Direct Plan - Growth Plan in the last three months

Overview

Expense ratio
Expense ratio
0.92%
Benchmark
Benchmark
S&P BSE Healthcare PR
AUM
AUM
₹7133 Cr
Inception Date
Inception Date
1 January, 2013
Min Lumpsum/SIP
Min Lumpsum/SIP
₹5000/₹100
Exit Load
Exit Load
1%
Lock In
Lock In
No Lock-in
TurnOver
TurnOver
18.67%

Nippon India Pharma Fund - Direct Plan - Growth Plan Distribution as on (30-Apr-24)

  • Equity 96.2%

  • Debt & Cash 3.8%

Size breakup

Large cap
40.4%
Mid cap
32.7%
Small cap
23.1%
Sector Allocation

Apr'24

Mar'24

Feb'24

Health
100%

Top Holdings of Nippon India Pharma Fund - Direct Plan - Growth Plan as on (30-Apr-24)

  • Equity

Equity Holdings31

Monthly Changes Updates

All changes are between Feb'24 and Apr'24
Fund Performance
Apr'24
Mar'24
Feb'24
Fund Returns
-0.00%
-0.14%
3.21%
Nifty 500
2.46%
-0.47%
1.58%
  • This fund’s returns stands at -0.00% whereas the fund’s underlying benchmark Nifty 500 returns stands at 2.46% as on Apr'24
  • This fund underperformed Nifty 500 by 2.47% in Apr'24
AUM Change
Parameters
Apr'24
Mar'24
Feb'24
AUM
₹ 7.1K Cr
₹ 7.1K Cr
₹ 7.1K Cr
  • AUM of the fund stands at 7.1K Cr as of Apr'24
  • AUM increased by 7.5 Cr between Apr'24 and Mar'24
Fund Portfolio Changes

Mutual Fund Insights

Insights icon
This fund has one of the lowest expense ratio in the category (sector - healthcare). Its expense ratio is 0.92% which is lower than the category average expense ratio of 1.42%.
Insights icon
In the last 5 years, DSP Healthcare Fund Direct Growth has given 29.05% return, outperforming this fund by 2.67% per annum.
Insights icon
In the last 1 year, ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth has given 58.21% return, outperforming this fund by 3.32%.
Insights icon
Over the last 1 year, this fund has decreased expense ratio by 27.0% moving from 1.26 to 0.92.
Insights icon
In the last 3 years, DSP Healthcare Fund Direct Growth has given 18.27% return, outperforming this fund by 2.27% per annum.
Insights icon
Over the last 6 months, this fund has experienced a 28.8% growth in AUM moving from 5.53K Cr to 7.13K Cr.
Insights icon
This fund with AUM at ₹7132.81Cr is among the largest funds in the sector - healthcare category.

INDmoney Rank

Powered by IND quant engine
IND ranking is not available for this fund.

Pros

Among most bought funds within the category
Larger AUM within category
Beats FD returns for both 3Y & 5Y duration

Cons

No bad points found for this fund.

Fund Manager

Sailesh Raj Bhan
Sailesh Raj Bhan
Fund Manager of Nippon India Pharma Fund - Direct Plan - Growth Plan, since 1 April 2005
Kinjal Desai
Kinjal Desai
Fund Manager of Nippon India Pharma Fund - Direct Plan - Growth Plan, since 25 May 2018

Nippon India Pharma Fund - Direct Plan - Growth Plan Highlights

Risk meter
pointer

Very High Risk

Investors understand that their principal will be at Very High Risk
About the fund

About the fund

This fund has delivered an average annual returns of 18.45% since inception which is less than its category average return of 20.92%
Fund Allocations

Fund Allocations

This fund has an allocation of 96.16% in Equity, 0% in Debt and 3.84% in Cash related instruments
AUM size ₹7133 Cr

AUM size ₹7133 Cr

This fund has AUM of ₹7133 Cr which is more than its category average of ₹ 1663 Cr
Expense Ratio 0.92%

Expense Ratio 0.92%

This fund has an expense ratio of 0.92% which is less than its category average expense ratio of 1.45%

Frequently Asked Questions

The current NAV of Nippon India Pharma Fund - Direct Plan - Growth Plan is ₹478.69 as on 17-May-2024.
Existing (Absolute + CAGR) as on 17-May-2024.
Nippon India Pharma Fund - Direct Plan - Growth Plan
Absolute Returns
CAGR Returns
1 Month Returns
2.55%
2.55%
6 Month Returns
18.59%
18.59%
1 Year Returns
54.89%
54.89%
3 Years Returns
56.09%
16%
5 Years Returns
222.39%
26.38%
With INDmoney, the process of investing is very simple and involves zero commission.
  • Click Buy on the fund name.
  • Input the amount you are looking to invest.
  • Select Lump Sum or SIP (Weekly, Monthly or Quarterly).
  • Select your bank account and proceed with Payment.
0.92% as on April 2024
₹7133 Cr as on April 2024
Sun Pharmaceuticals Industries Ltd(13.81%), Lupin Ltd(8.55%), Cipla Ltd(6.08%), Apollo Hospitals Enterprise Ltd(5.41%), Divi's Laboratories Ltd(5.05%) as on April 2024
The alpha ratio for the Nippon India Pharma Fund - Direct Plan - Growth Plan for various period is as follows:
Fund Name
Alpha 1 Year
Alpha 3 Years
Alpha 5 Years
Nippon India Pharma Fund - Direct Plan - Growth Plan
0.16
1.7
3.66
As on April 2024
The alpha for Nippon India Pharma Fund - Direct Plan - Growth Plan is calculated against S&P BSE Healthcare PR. Higher alpha indicates that this fund has generated extra returns compared to the benchmark index. An alpha of 1.0 means the fund has outperformed its benchmark index by 1%.
The Beta ratio for the Nippon India Pharma Fund - Direct Plan - Growth Plan for various period is as follows:
Fund Name
Beta 1 Year
Beta 3 Years
Beta 5 Years
Nippon India Pharma Fund - Direct Plan - Growth Plan
0.96
0.95
0.92
As on April 2024
The Beta for Nippon India Pharma Fund - Direct Plan - Growth Plan is calculated with S&P BSE Healthcare PR. Beta tells the volatility of the mutual fund relative to its benchmark. If the beta of a mutual fund is more than 1, then the mutual fund is more volatile than its benchmark. If beta is less than 1, then the mutual fund is less volatile than the benchmark.
The sharpe ratio for the Nippon India Pharma Fund - Direct Plan - Growth Plan for various period is as follows:
Fund Name
Sharpe Ratio 1 Year
Sharpe Ratio 3 Years
Sharpe Ratio 5 Years
Nippon India Pharma Fund - Direct Plan - Growth Plan
2.51
0.78
0.97
As on April 2024
The sharpe ratio for Nippon India Pharma Fund - Direct Plan - Growth Plan is calculated with S&P BSE Healthcare PR. Sharpe ratio tells risk-adjusted-returns of the mutual fund. The higher a fund's Sharpe ratio, the better a fund's returns have been relative to the risk it has taken on.
The standard deviation for the Nippon India Pharma Fund - Direct Plan - Growth Plan for various period is as follows:
Fund Name
Standard Deviation 1 Year
Standard Deviation 3 Years
Standard Deviation 5 Years
Nippon India Pharma Fund - Direct Plan - Growth Plan
14.76
14.61
18.62
As on April 2024
Standard deviation tells the volatility of the returns of the mutual fund. The higher a fund's Standard deviation, the higher the volatility of the fund's returns.
Sortino ratio is 1.33 as on April 2024. Sortino ratio tells the downside risk-adjusted-returns of the mutual fund.
Information ratio is 0.58 as on April 2024. It tells the consistency of the fund in generating superior risk-adjusted performance
Sailesh Raj Bhan, Kinjal Desai are the fund managers of Nippon India Pharma Fund - Direct Plan - Growth Plan
The Exit load of Nippon India Pharma Fund - Direct Plan - Growth Plan is 1%